US Corporate Distress Financial Stress SEC Filings — October 22, 2026

Claims regained Nasdaq stockholders' equity compliance after the Oct 13, 2026 Velaris merger and ~$350.0M gross private placement closed Oct 14, 2026; pre-transaction equity was only $2.153M per FY2025 10-K, so the capital raise is the driver

Nasdaq Panel hearing set for Nov 10, 2026 is cancelled only upon Staff confirmation, which is not assured; Series B and most Series C preferred expected to sit outside permanent equity pending stockholder approvals

Pre-arranged Chapter 11 (S.D. Texas, Case No. 26-90795) backed by an RSA with term-loan lenders under the Mar 9, 2021 credit agreement; disclosure statement and plan filed Oct 20, 2026, indicating the lender-led path is advancing [BEARISH for equity]

Common stock delisted and trading on Pink Limited Market as LESLQ since Oct 6, 2026; company explicitly warns equity holders may suffer significant loss on confirmation

Filed the 2025 10-K on Oct 16, 2026 after missing the Oct 12 extension deadline, but still owes Q1 and Q2 2026 10-Qs; Hearings Panel request due Oct 23, 2026 with auto 15-day stay, hearing typically 30-45 days out

Closed below $1.00 for 30 consecutive business days (Nasdaq Rule 5550(a)(2)); compliance deadline April 19, 2027 requires 10 consecutive days at or above $1.00; notice has no immediate listing effect

May qualify for a second 180-day cure period if it meets market value of publicly held shares and other initial listing standards and gives written notice of intent to cure

Q3 2026 10-Q will not reflect the merger or financing, so the reported equity improvement will appear only in later filings, creating a near-term disclosure gap

Plan confirmation may wipe out or heavily dilute common equity; stock already delisted to Pink Limited Market (LESLQ) since Oct 6, 2026

Chapter 11 across nine subsidiaries with a joint plan and RSA-driven timeline; creditor-led restructuring leaves little room for shareholder recovery

Missed 10-K and two 10-Q filings past a 180-day extension; Staff Delisting Determination issued Oct 16, 2026; suspension at end of 15-day stay if Panel does not extend or reinstate

Two outstanding 10-Qs (Q1 and Q2 2026) mean investors lack current financial information, compounding the delisting and valuation uncertainty

Continued listing depends on evidencing equity compliance in the FY2026 10-K; failure triggers delisting despite the current claim of compliance

Series B and most Series C preferred classified outside permanent equity pending stockholder approvals; approval failure or delay could revive the equity deficiency

Waiver terminates only on later of Series C conversion approval and authorized-share-increase effectiveness; unresolved features could reintroduce obligations

Sub-$1 trading for 30 consecutive business days; if not cured by Apr 19, 2027 or ineligible for second period, a delisting notice follows and appeal success is not assured

~$350.0M gross private placement and Velaris merger lift equity from a $2.153M baseline; if Nasdaq Staff confirms compliance before Nov 10, 2026, the Panel hearing is cancelled and listing overhang lifts

Stockholder approvals for Series C conversion and authorized-share increase will determine both preferred classification and cash settlement right termination; successful votes remove key overhangs

Disclosure statement and plan filed Oct 20, 2026 under RSA; confirmation timing and any equity recovery terms are the key event for distressed-equity or claims-based positioning [OPPORTUNITY, speculative]

A timely Oct 23, 2026 hearing request plus a granted extended stay would preserve trading while the company completes 10-Q filings; a favorable post-hearing decision could reinstate listing [OPPORTUNITY, high-risk]

A second 180-day cure period is available if eligibility criteria and written intent-to-cure notice are satisfied, giving time to reach $1.00 for 10 consecutive business days before April 2027

Three of four filings (SenesTech, Alaunos, Atlantic American) involve Nasdaq deficiency notices or determinations across bid-price, equity, and filing-delinquency rules, indicating active exchange enforcement against sub-scale or late-filing issuers [pattern to monitor]

Leslie's illustrates the lender-driven Chapter 11 pattern where RSA-backed plans consolidate control with creditors and disadvantage common shareholders; delisting to Pink markets typically precedes equity impairment [implication: avoid long-only equity exposure in RSA-backed cases]

Alaunos shows that large private placements combined with mergers can rapidly restore equity-based listing standards, but preferred-stock classification and approval dependencies mean cures can be contingent [implication: verify approval-dependent compliance]

Atlantic American's missed 10-K and 10-Q deadlines show that reporting failures, not only financial metrics, trigger delisting, a risk for issuers in restatement or audit-delay situations [implication: track late-filer notices as early distress signals]

Hearing Nov 10, 2026; watch for Staff confirmation of compliance that would cancel it, and FY2026 10-K equity disclosure

Votes on Series C conversion and authorized-share increase; outcome determines preferred classification and cash settlement waiver

Deadline Oct 23, 2026; watch for extended stay decision and date of hearing (typically 30-45 days after request)

Q1 and Q2 2026 Forms 10-Q outstanding; filing completion is the key condition for regaining compliance

Plan and disclosure statement (Docket Nos. 166, 167) filed Oct 20, 2026; monitor confirmation schedule and equity treatment

Pink Limited Market trading since Oct 6, 2026; watch for liquidity and any further equity-treatment disclosures

Compliance deadline April 19, 2027; watch for written intent-to-cure notice and any reverse split or price recovery

Confirm market value of publicly held shares and other initial listing standards to determine eligibility for an additional 180 days